Kornimate/medical-research-clean huggingface dataset:
efficiency of an optimized care organization for fibromyalgia patients. the fimouv 2 study

Conditions: Fibromyalgia; Physical Activity

Summary: fibromyalgia affects 2 to 5% of adults in the general population. patients describe a combination of symptoms centred around fatigue not induced by exercise and not relieved by rest. the diagnosis of fibromyalgia is self-perpetuating by the deconditioning, consequence of a reduced muscle mass due to inactivity and periods of prolonged rest. thus, it seems fundamental to develop other non-drug approaches: among them, adapted physical activity is recommended by most learned societies because of a good level of evidence (level 1, grade a). the question remains, however, whether simple advice to resume physical activity is sufficient (routine care with medical assessment at 3 months) or whether a physical activity supervised inside and outside the hospital is not more relevant.

in order to set up an optimal patient path within the group of hospitals of loire territory, the working group composed of doctors from different specialities of the department considered it important to carry out a randomised study evaluating the effectiveness of a healthcare organisation combining: * an adapted and supervised physical activity intervention (1 month hospital initiation then 2 months in town) * therapeutic education sessions for the patient with motivational interviews compared to usual clinical practice (adapted physical activity adapted in autonomy at home + therapeutic patient education sessions with motivational interviews).

Eligibility criteria:
inclusion criteria: * patient diagnosed with fibromyalgia according to acr (american college of rheumatology) criteria (total score wpi (widespread pain index) + ss (severity scale) ) ≥ 13 * french writing and speaking * sedentary or low level of activity (less than 150 minutes of regular physical activity per week at the time of inclusion) * signature of informed consent exclusion criteria: * cardiac or respiratory diseases that contraindicate the practice of physical activity * significant co-morbidities that contraindicate the practice of physical activity: associated cardiac pathologies (severe rhythm disorders such as rapid atrial fibrillation), respiratory pathologies (severe obstructive or severe respiratory insufficiency), disabling joint pathologies (knee osteoarthritis or osteoarthritis of the hip) training on a treadmill or on a high intensity bike). * impossibility of submitting to the medical monitoring of the program for geographical, social or psychological reason

Keywords: sedentary time therapeutic education sessions
curve of spee: speed of leveling using different orthodontic archwires

Conditions: Orthodontic Treatment

Summary: the objectives if this study was to evaluate the efficacy of 3 different rectangular archwires in the correction of the curve of spee (cos), to record the time needed to level excessive cos in the mandibular arch using the 3 archwire sizes, to investigate the changes in intercanine and intermolar widths and arch length during leveling, to measure the arterio-posterior and vertical movement for the lower incisors and lower molars, to record pulpal blood flow and to detect the root resorption in the lower anterior teeth associated with leveling excessive cos using the 3 different archwires.

fifty one subjects with an excessive cos were included in this study. the subjects will be randomly divided into three groups; group one (17 patients): leveling of cos using 0.017x0.025-inch stainless steel archwire. group two (17 patients): leveling of cos using 0.019x0.025-inch stainless steel archwire. group three (17 patients): leveling of cos using 0.021x0.025-inch titanium molybdenum archwire. in the three groups, a 5mm depth reverse cos will be inserted. records consisted of lateral cephalograms (pre-treatment, at t0 and post-treatment), peri-apical radiographs (at t0 and at t5), study casts (pre-treatment and at each time point during the tudy). patients will be followed up on monthly visits without removing leveling archwires where alginate impressions were taken for the lower arch. pain scores during the first week of leveling will be recorded using visual analogue scale (vas).the amount of cos correction in mm, changes in intercanine in mm, intermolar and arch length in mm, pain scores and lower incisors root resorptions in mm will be measured.

Eligibility criteria:
inclusion criteria: * age ≥ 16 years and ≤ 30 years * overbite covering more than half of the lower incisor height * curve of spee ≥ 4 millimeters * mild crowding in lower arch where non-extraction treatment is indicated. * normally inclined or retroclined lower incisors * averaged or reduced lower vertical height * good oral hygiene and healthy periodontium * all permanent teeth are present except for the third molars exclusion criteria: * severe crowding in lower arch where extraction treatment is indicated. * missing permanent molars or premolars * poor oral hygiene and periodontal disease * systemic health problems and medications were taken * history of previous orthodontic treatment * smoking

Keywords: root resorption pain pulpal blood flow
study assessing long-term outcomes of dupilumab (dupixent®) treatment in adult patients with chronic rhinosinusitis with nasal polyposis (crswnp)

Conditions: Chronic Rhinosinusitis With Nasal Polyposis

Summary: the primary objectives of the study are: * to longitudinally characterize the long-term effectiveness of dupixent® through assessment of patient-reported symptoms, health-related quality of life (hrqol) related to chronic rhinosinusitis with nasal polyposis (crswnp) and other type 2 comorbidities, and their change over-time. * to characterize patients who receive dupixent® for crswnp in a real-world setting with respect to their medical history, demographic and disease characteristics, and type 2 comorbidities the secondary objectives of the study are: * to characterize real-world utilization of dupixent® for patients with crswnp * to collect patient and physician global assessment of disease severity and treatment satisfaction for patients receiving dupixent® for crswnp * to collect long-term safety data for patients receiving dupixent® for crswnp


Eligibility criteria:
key inclusion criteria: * all patients who are newly initiated on dupixent® for the treatment of crswnp according to the respective prescribing information (product label or smpc) * willing and able to comply with clinic visits and study-related procedures as per protocol * provide informed consent signed by study patient or legally acceptable representative * able to understand and complete study-related questionnaires as per protocol key exclusion criteria: * patients who have a contraindication to dupixent® according to the country-specific prescribing information * any previous treatment with dupixent® for any condition * any condition that, in the opinion of the investigator, may interfere with the patient's ability to participate in the study per protocol * participation in an ongoing interventional or observational study that might, in the treating physician's opinion, influence the assessments for the current study per protocol

Keywords: crswnp
strongyloides stercoralis in bone marrow transplant recipients in the uk

Conditions: Strongyloidiasis; Bone Marrow Transplant Infection

Summary: strongyloidiasis is a worm infection which affects more than 100 million people, mostly in africa, asia and latin america, and can cause severe illness in people with reduced immunity. in the uk, the number of people with strongyloides is not known. at imperial college healthcare nhs trust (ichnt) , screening for stongyloides has recently been introduced as a standard-of-care for all patients undergoing bmt. in this study, investigators will perform two cross-sectional surveys and report the prevalence of strongyloides in bmt recipients at ichnt , as well as comparing clinical outcomes before/after the introduction of routine testing.

strongyloidiasis is a worm infection which affects more than 100 million people, mostly in africa, asia and latin america. infection can persist for decades, and usually causes mild symptoms. in some people with reduced immune systems (for example those who have bone marrow transplantation), the worms can multiply and cause severe illness and death. in the uk, the number of people with strongyloides is not known. however, in many other non-tropical countries, rates are high in immigrant populations (including those who are having bone marrow transplantation, bmt). at ichnt, screening for stongyloides has recently been introduced as a standard-of-care for all patients undergoing bmt. all adult patients with forthcoming bmt at ichnt will now be screened. additionally, any patients who have already undergone bmt in the last two years will be screened as part of a look-back exercise as part of their clinical care. in this study, investigators will perform two cross-sectional surveys. those who underwent bmt between jun 2018 - july 2020 will form a 'pre-screening group', and those between july 2020 - july 2021 will form a 'screened group'. it is anticipated that 320 participants will be included in the pre-screening group and 160 in the screened-group (total 480). data will be collected retrospectively and the prevalence of strongyloides in bmt recipients at ichnt will be reported. comparison of clinical outcomes between the first and second groups will be undertaken, in order to determine whether the introduction of screening has had an impact.

Eligibility criteria:
inclusion criteria: * adult patients * under care of haematology at ichnt * undergoing bmt jun 2018 - july 2020 ('pre-screening group') or july 2020 - july 2021 ('screened group') exclusion criteria: * age \< 18 years (i.e. managed as paediatric bmt) * previous bmt but no strongyloides serology result available at the time of data collection
fnb in acl recon under ga

Conditions: Anterior Cruciate Ligament Rupture; Femoral Nerve Block

Summary: the investigators will compare the results of sono-guided femoral nerve block in arthroscopic surgery for anterior cruciate ligament reconstruction under general anesthesia.

this study is a randomized controlled trial of 100 patients, who underwent history taking, physical examinations, x-rays, and mri or ultrasonography, and were diagnosed with anterior cruciate ligament rupture from september 2023 to august 2028. the 100 patients will be assigned to group i (with femoral nerve block) or group ii (without femoral nerve block) under double-blinded randomization. the randomization will be performed by an independent nurse using a computerized random sequence generator. the operators who participated in the procedure will be blinded to the participant's information. both group will undergo general anesthesia for arthroscopic anterior cruciate ligament reconstruction. after anesthesia, sono-guided femoral nerve block will be performed. the injection for group1 is 20 ml ropivacaine and for groupii is 20 ml 0.9% saline. a visual analog scale (vas) for pain will be recorded 1, 3, 6, 12, 18, 24, 36, 48 hours after the operation. vas scores range from 0 to 10, with 0 being no pain and 10 being the most severe pain ever experienced. injection with ultrasonography will be performed by a single anesthesiologist. 3 orthopedic surgeons will perform the surgery.

Eligibility criteria:
inclusion criteria: * individuals who are scheduled to undergo arthroscopic anterior cruciate ligament reconstruction surgery and must be received sufficient explanation about the research prior to surgery and have provided their informed consent to participate. exclusion criteria: * who require simultaneous surgery for concomitant cartilage injury, medial meniscus tear, and lateral collateral ligament tear. * who have previously undergone surgical treatment within the knee joint. * who have declined to participate in the research. * where medical, surgical, or anesthetic complications occurred during surgery. * other cases deemed necessary by the researchers.
clinical trial of cbasp for individuals with co-occurring chronic depression and alcohol dependence

Conditions: Depressive Disorder; Major Depressive Disorder; Dysthymic Disorder; Alcohol-Related Disorders; Alcoholism

Summary: this study examines the effectiveness of cognitive behavioral analysis system of psychotherapy (cbasp) in reducing both alcohol consumption and depressive symptoms in adults who are chronically depressed and alcohol dependent.

this study examines the effectiveness of cognitive behavioral analysis system of psychotherapy (cbasp) in reducing both alcohol consumption and depressive symptoms in adults who are chronically depressed and alcohol dependent. participants will receive a 20-session course of cbasp psychotherapy over a period of 21 weeks and will be assessed for severity of pretreatment psychological abuse and trauma as well as pre and posttreatment interpersonal functioning. two primary hypotheses are to be tested: 1) demonstrate that cbasp is effective in reducing depressive symptoms (hamilton rating scale for depression-24 ratings) and alcohol consumption (drinks per drinking day) in this chronically depressed alcohol dependent cohort when posttreatment ratings are compared to pretreatment levels; and 2) demonstrate that acquisition of feeling safe with the therapist and acquisition of the ability to perceive the interpersonal consequences of one's behavior will significantly increase from pre to posttreatment levels and will be associated with reductions in drinking and depressive symptoms.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of a current major depressive disorder (e.g., major depression, dysthymic disorder) for a minimum of two years * clinical diagnosis of alcohol dependence during the last thirty days * interest in changing one's drinking and alleviating depressive symptoms exclusion criteria: * please call study site for additional information
pilot trial of homebound stem cell transplantation

Conditions: Plasma Cell Dyscrasia

Summary: in this study, the investigators plan to see what happens when a person receives care in the home setting. they want to find out if caring for a patient who has been treated with an asct in the home setting is feasible. they want to find out what effects good and/or bad this will have on the patient's recovery and treatment after asct. studies in other institutions have shown that providing care in the home setting after asct is safe, increases patient satisfaction, and can decrease the risk of infection. it is our hope that this new approach of providing care in the home setting will prove to be a feasible and safe option for patients at memorial sloan kettering cancer center (msk).


Eligibility criteria:
inclusion criteria: * diagnosis of plasma cell dyscrasia * treatment plan including autologous hsct * 18-80 years of age * appropriate homebound setting as defined by one of the following: * lodging at the msk residence. * staying at home or a "home equivalent" in any one of the zip codes as outlined in the appendix. home equivalent is defined as a residence which may or may not be the primary residence of the patient. * "home equivalent" must pass the "home environment screening tool" for homebound stem cell transplantation (not required for other msk recognized lodging facility). * adequate caregiver support as defined by: * single or multiple informal caregivers willing and able to provide 24 hour a day, seven day a week supervision of the transplant recipient in their home or "home-like" environment. * caregiver willing and able to fulfill the basic stem cell transplant caregiver education requirements as determined by caregiver and healthcare team, including social worker * have wi-fi connection * appropriate third party payer coverage for "homebound stem cell transplant program" * both patient and caregiver willing to give and sign informed consent. exclusion criteria: * patients with a documented active infection prior to starting their preparative regimen. this includes grade 3 or higher viral, bacterial, or fungal infection. * uncontrolled arrhythmias * active or uncontrolled pulmonary disease * karnofsky performance scale (kps) score \<80 * sorror co-morbidity index ≥ 4 except in patients with history of resected cancers * creatinine clearance (calculated or measured) of \< 50 cc/minute * inability of patient or caregiver to speak or read english (we currently do not have the manpower to translate nor staff a multilingual homebound stem cell transplant program with adequate educational materials). * inadequate housing arrangements * inadequate caregiver arrangements

Keywords: homebound homecare 15-022
power doppler in hand joints of early ra patients

Conditions: Early Rheumatoid Arthritis

Summary: it is a prospective case-control study with women diagnosed early rheumatoid arthritis. three therapeutic failures were considered: failure 1 - to the first disease-modifying antirheumatic drugs (dmards) (methotrexate); failure 2 - to the second dmards (leflunomide) and failure 3 - to the first immunobiological drugs (adalimumab). ultrasound was performed bilaterally on the 2nd and 3rd metacarpophalangeal joints (mcfs), proximal interphalangeal joints (ifps), and wrists (us10). ultrasound measurements (qualitative and semi-quantitative) evaluated: 1 - inflammatory: synovial and tenosynovial proliferation in gray scale and power doppler (0-3); 2 - joint damage: bone erosion (qualitative and semi-quantitative) and cartilage damage (qualitative and semi-quantitative). clinical and laboratory variables were also assessed blindly at baseline and after 12, 24 e 48 weeks.


Eligibility criteria:
inclusion criteria: * early rheumatoid arthritis fulfilment of the 2010 acr/eular ra classification criteria; * age between 18-65 years; * female gender, * naive for treatment. exclusion criteria: * use of oral \> 10 mg/d glucocorticoid in the previous three weeks; * serum aspartate aminotransferase or alanine aminotransferase level \> 3 times the upper limit of normal; * bone marrow, auto-imune, lymphoproliferative or infectious diseases; * pregnancy.
belumosudil and rituximab for primary treatment of chronic graft-versus-host-disease

Conditions: Chronic Graft Versus Host Disease

Summary: this is an open-label, phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cgvhd.


Eligibility criteria:
inclusion criteria: * first episode of systemic immunosuppression-requiring cgvhd, defined as classic cgvhd by the nih consensus criteria (without features or characteristics of agvhd) * previously untreated, defined by having received \<10 days of corticosteroids or alternative systemic immunosuppressive agent started specifically for a new diagnosis of cgvhd * kps \>/= 70% * adequate hematologic function independent of platelet transfusion and g-csf for at least 7 days prior to study entry: anc \>750 cells/mm3; platelets \>30,000 cells/mm# exclusion criteria: * late persistent or recurrent agvhd * active uncontrolled infection * history of hiv infection * active hbv or hcv infection. subjects who are positive for hepatitis b core antibody, hepatitis b surface antigen, or hepatitis c antibody must have a negative pcr result before enrollment. those who are pcr positive will be excluded. * calculated crcl \<30ml/min * ast and/or alt \>5x uln or direct bilirubin \>3x uln * cardiac ejection fraction \<40% or history of uncontrolled cardiac arrhythmias * has received more than one allogeneic transplant prior to the occurrence of cgvhd
cholecalciferol supplementation on disease activity, fatigue and bone mass on juvenile systemic lupus erythematosus.

Conditions: Systemic Lupus Erythematosus

Summary: the potential role of vitamin d on disease susceptibility, activity and severity has been considered for several autoimmune rheumatologic diseases include systemic lupus erythematosus (sle) . although, there are few studies of vitamin d supplementation in sle patients, especially in juvenile onset systemic lupus erythematosus (josle). the objective of this study is to evaluate the effect of vitamin d supplementation (cholecalciferol 50.000 international units (iu)/week for 24 weeks) on disease activity (clinical and laboratory parameters), fatigue and bone mass.

this is a study 24-week, two arm, double blinded randomized clinical trial to evaluate the effects of high-dose vitamin d3 supplementation compared with placebo, on activity disease, fatigue and bone mass. sixty josle patients will be randomized to receive placebo or vitamin d3 (50.000 iu/week) for 24weeks. the patients return to visits in week 12 and week 24 for evaluation. study will record clinical history, drugs in use, disease activity, and bone mass parameters.

Eligibility criteria:
inclusion criteria: * written informed consent signed * 4 of the 11 modified american college of rheumatology (acr) revised criteria for the classification of systemic lupus erythematosus . * sledai \< 8 at screening and at baseline * stable immunosuppressive dose prior to randomization. * body mass index \< 30 * able to swallow pills at randomization exclusion criteria: * refuse of the patient or the legal responsible * use of vitamin d2 or d3 supplementation * significant renal insufficiency * primary hyperparathyroidism (known) * history of nephrolithiasis (known) * diabetes mellitus requiring insulin therapy * history of vertebral compression fractures (known) * pregnancy * use of bisphosphonates

Keywords: lupus juvenile cholecalciferol disease activity bone mass fatigue safety